Join Medicilon at APT 2023 | Focus on Medicilon's Toxicology Services

The Boston Society is a non-profit organization founded in 2004 as an organization that promotes education, training, discussion, and scientific events in support of drug discovery, development, and related topics. 

The Applied Pharmaceutical Toxicology (APT) 2023 sponsored by Medicilon will kick off in the United States on May 16, 2023, and the conference will last for three days. 

Dr. Chunlin Chen, founder & CEO of Medicilon, and the American team will be present throughout the whole process. Dr. Renzong Xie, vice president of Medicilon Toxicology Research Department, will give a speech "Nonclinical Safety Evaluation of Nanolipid  Particles" at 3:30-3:40 local time on May 17, we sincerely invite you to visit us at booth #7!

About Medicilon

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. We provide one-stop customized R&D solutions ranging from precise drug targeting to IND filing assistance. Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.

Toxicology Services in Medicilon

Medicilon specializes in preclinical toxicology. Our worldwide clients benefit from a full range of safety assessment services that range from rapid lead optimization through fully GLP-compliant toxicology studies. With more than 1,000 experts, we offer you the broadest and deepest bench of professionals in the industry.

Species

•     Mice

•     Rats

•     Guinea Pigs

•     Rabbits

•     Beagles

Administration Routes

•     Implant

•     Inhalation

•     Intradermal

•     Intramuscular

•     Intraperitoneal

•     Intravenous

•     Rectal

•     Subcutaneous

•     Vaginal